INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
06 Februar 2024 - 3:00PM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company targeting
microglial activation and neuroinflammation as a cause of
Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a
dominant-negative inhibitor of soluble TNF, announces its
management will be participating in Baird’s Biotech Discovery
Series webcast on Tuesday, February 13, 2024 at 10:30AM EST.
The webcast will feature RJ Tesi, MD, CEO, CJ Barnum, PhD, head of
Neuroscience, and Malu Tansey, PhD, Professor of Neuroscience and
Neurology, Norman and Susan Fixel Chair in Parkinson’s Disease,
Director, Parkinson’s Foundation Research Center of Excellence,
University of Florida.
The speakers will cover two key topics – first, they will
provide an update on the unique features of the Company’s
ongoing blinded, randomized, placebo-controlled Phase II trial for
Early Alzheimer's disease (MCI/Mild AD). Additionally, the
group will highlight the predecessor Phase I trial data that
demonstrated that neutralizing soluble TNF with XPro™ and
preserving transmembrane TNF function
decreased neuroinflammation (decreased inflammatory cytokines
in the CFS and decrease White Matter Free Water in white matter
tracts), decreased neurodegeneration (46% decrease in pTau217; 84%
decrease in NFL), improved synaptic function and
promoted remyelination of axons.
Those who wish to view the discussion can register for the
webcast by clicking here.
Link:
https://goto.webcasts.com/starthere.jsp?ei=1655791&tp_key=48e19840e0&sti=gib
Baird’s Biotech Discovery Series, which launched in early 2022,
is an opportunity for investors to hear directly from interesting
and innovative public and private biotech companies in a fireside
chat format. Each episode is centered around a key event for the
focus company, which can include new clinical data, a material
regulatory event, key management additions, a significant new
investment, a key acquisition, new entry into the public markets,
etc. We invite key members of management and frequently ask related
third parties to join the discussion to learn why they are excited
about the science and opportunity for these emerging biotech
leaders.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on
developing treatments that target the innate immune system to fight
disease. INmune Bio has two product platforms that are both in
clinical trials: The Dominant-Negative Tumor Necrosis Factor
(DN-TNF) product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. XPro™, first
of several DN-TNF products, is in clinical trials to determine if
it can treat patients with Early Alzheimer’s disease. . The
Natural Killer Cell Priming Platform includes INKmune™, a therapy
developed to prime a patient’s NK cells to treat patients with
cancer. INKmune™ uses a precision medicine approach for the
treatment of a wide variety of hematologic and solid tumor
malignancies. The INKmune™ trial is enrolling patients into a
US Phase I/II trial in men with metastatic castrate resistant
prostate cancer and into a Phase I program in MDS/AML in
Europe. To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595, and INKmune™
are still in clinical trials or preparing to start clinical trials
and have not been approved by the US Food and Drug Administration
(FDA) or any regulatory body and there cannot be any assurance that
they will be approved by the FDA or any regulatory body or that any
specific results will be achieved. The factors that could cause
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720 info@inmunenbio.com
Investor Contact: Jason Nelson, Core IR (516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024